Suggested Readings
Update οn the diagnosis and management of systemic lupus erythematosus.
Fanouriakis A, et al. Ann Rheum Dis. 2021;80(1):14-25.
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R, et al. Arthritis Rheum. 2011;63(12):3918-3930.
All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study.
Moghaddam B, et al. Rheumatology. 2021;61(1):367-376.
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.
Morand EF, et al. Lancet Rheum. 2022;4(4):E282-E292.
Trial of anifrolumab in active systemic lupus erythematosus.
Morand EF, et al. N Engl J Med. 2020;382(3):211-221.
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Navarra SV, et al. Lancet. 2011;377(9767):721-731.
The pathogenesis, molecular mechanisms, and therapeutic potential of the interferon pathway in systemic lupus erythematosus and other autoimmune diseases.
Ramaswamy M, et al. Int J Mol Sci. 2021;22(20):11286.
Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study.
Ruiz-Arruza I, et al. Arthritis Care Res. 2018;70(4):582-591.
SLE mortality remains disproportionately high, despite improvements over the last decade.
Singh RR, Yen EY. Lupus. 2018;27(10):1577-1581.
Linked Resources
YOUTUBE VIDEOS
Hot Topics Lupus: Overcoming Patient Barriers
CLASSIFICATION CRITERIA
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.
Aringer M, et al. Arthritis Rheumatol. 2019;71(9):1400-1412.
DISEASE MANAGEMENT GUIDELINES
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Fanouriakis A, et al. Ann Rheum Dis. 2019;78(6):736-745.
PATIENT RESOURCES
American College of Rheumatology
Lupus Foundation of America
Lupus Research Alliance
Related activities
Webcast Series
0.25 CME/CE
SLE Pathophysiology
Module 1
Faculty: | Elena M. Massarotti, MD |
Release: | 05/30/2023 |
Expiration: | 05/30/2024 |
Webcast Series
0.25 CME/CE
Individualizing Steroid-Sparing Regimens in SLE
Module 2
Faculty: | Elena M. Massarotti, MD |
Release: | 05/30/2023 |
Expiration: | 05/30/2024 |
Webcast Series
0.25 CME/CE
Targeted Biologic Treatment Options in SLE
Module 3
Faculty: | Elena M. Massarotti, MD |
Release: | 05/30/2023 |
Expiration: | 05/30/2024 |